Edmonton, Alberta, Canada, December 13, 2021 -- Pacylex today announced that data from the first ever clinical trial of an N-myristoyltransferase (NMT) inhibitor was presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. This update included the design of the first clinical trial with PCLX-001 in Non-Hodgkin's Lymphoma and solid tumor patients and an update on the first dose cohort. Details of the poster are below.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• This presentation included the design of the first clinical trial with PCLX-001 in Non-Hodgkin's Lymphoma and solid tumor patients and an update on the first dose cohort.
• No dose-limiting toxicities have been identified. Preliminary pharmacokinetic analysis shows rapid oral absorption, an elimination half-life of ~ 12 hours, and no plasma accumulation.
• In addition to the presentation, the abstract was published online in the November supplemental issue of Blood.

Click image above to view full announcement.

PCLX-001

PCLX-001 (aka DDD86481) is a first-in-class, small molecule NMT inhibitor originally developed by the University of Dundee Drug Discovery Unit as part of a program to treat African sleeping sickness, funded by Wellcome Trust. Pacylex is developing PCLX-001 in the form of a once-a-day pill initially to treat leukemia and lymphoma. PCLX-001 has also been shown to inhibit the growth of lung and breast cancer tumors in animal models. In leukemia, lymphoma, and breast cancer patients, the levels of NMT2 is correlated with survival, suggesting an important biological role in these cancers. In tests using cultured cancer cells in vitro, PCLX-001 is at least ten times as potent as ibrutinib (Imbruvica) and dasatinib (Sprycel), two clinically approved drugs currently used to treat hematologic malignancies.

About Pacylex

Pacylex is a pharmaceutical company targeting hematologic and solid cancers with a new first-in-class therapeutic, headquartered in Edmonton, Alberta, Canada. Pacylex's technology combines new insights from Dr. Luc Berthiaume of the University of Alberta connecting myristoylation to cancer with a family of high quality myristoylation inhibitors Pacylex licensed from the University of Dundee. PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex initiated clinical studies in Canada in the fall of 2021 in diffuse large B-cell lymphoma and solid tumors. Pacylex is also receiving support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation.

For more information:

Pacylex Pharmaceuticals Contact: Michael J. Weickert, CEO of Pacylex Pharmaceuticals, Inc.

E: [email protected]

P: 650-218-1840

Twitter, LinkedIn, Facebook

Contacts:

Michael Weickert Ph.D

650-218-1840

[email protected]

Source: Pacylex

Distributed by: Reportable, Inc.